Wuxi Biologics Cayman Inc ADR (OP: WXXWY )

2.980 +0.040 (+1.36%)

Streaming Delayed Price Updated: 3:55 PM EDT, Jun 5, 2024 Add to My Watchlist

Price and Volume

Volume	68,845
Open	2.940
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	2.940
Today's Range	2.940 - 2.990
52wk Range	2.790 - 13.25
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities

March 23, 2024

Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility.

Via Talk Markets

Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus

March 14, 2024

Amidst regulatory challenges, WuXi AppTec faces backlash from industry giants. Biotechnology Innovation Organization cuts ties, citing national security concerns. Shares plummet as U.S. bills target...

Via Benzinga

Performance

YTD	-59.01%	-59.01%
1 Month	-19.89%	-19.89%
3 Month	-33.18%	-33.18%
6 Month	-61.84%	-61.84%
1 Year	-73.60%	-73.60%

More News

Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem

November 25, 2023

Via Talk Markets

Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal

November 18, 2023

Via Talk Markets

Week In Review: BeiGene Options DualityBio ADC In $1.3 Billion Agreement

July 15, 2023

Via Talk Markets

Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal

November 11, 2023

Via Talk Markets

Strong Consumer Turnout Drives Hong Kong Stocks Higher Friday As China's Former Premier Li Keqiang Dies At 68

October 27, 2023

Via Benzinga

Week In Review: China's Biopharmas Announce $2.5 Billion In Deals

October 21, 2023

Via Talk Markets

Week In Review: QYuns Plans Hong Kong IPO For Autoimmune/Allergic Disease Portfolio

October 07, 2023

Via Talk Markets

Week In Review: WuXi Biologics Out-Licenses Four TCE Antibodies To GSK In $1.5 Billion Pact

January 07, 2023

Via Talk Markets

Week In Review: Ten Biggest 2022 China Biopharma Deals Worth $21.5 Billion

December 31, 2022

Via Talk Markets

Wuxi Biologics Will Be Removed From U.S. Commerce Department's ‘Unverified List’

October 09, 2022

Via Talk Markets

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.